Why the study?
Does andexanet alfa reverse Factor Xa inhibition and restore thrombin generation?
Does andexanet alfa reverse Factor Xa inhibition and restore thrombin generation?
Andexanet alfa acts as a specific reversal agent for Factor Xa inhibitors by restoring thrombin generation without triggering prothrombotic activity.
Answers are grounded in this paper and cite their sources.
Andexanet alfa restores thrombin generation in volunteer studies; leaves open clinical safety and efficacy pending larger trials.
Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The molecule is a recombinant protein analog of factor Xa that binds to Factor Xa inhibitors and antithrombin:LMWH complex but does not trigger prothrombotic activity. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. Further trials are underway to examine its safety and efficacy in the population of patients experiencing FXa inhibitor-related bleeding.
No takes yet. Share an insight, caveat, or question.
Ghadimi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: